Oxford BioDynamics PLC Targets Amyotrophic Lateral Sclerosis in Asia (8725H)
13 June 2017 - 4:00PM
UK Regulatory
TIDMOBD
RNS Number : 8725H
Oxford BioDynamics PLC
13 June 2017
13 June 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics targets Amyotrophic Lateral Sclerosis in
Asia
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology
company focused on the discovery and development of epigenetic
biomarkers based on regulatory genome architecture, for use within
the pharmaceutical and biotechnology industry, is to expand its
Amyotrophic Lateral Sclerosis (ALS) biomarker programme into South
East Asia.
Since receiving funding through an Innovate UK grant in December
2014, OBD has been leading a consortium, including the Nuffield
Department of Clinical Neurosciences (University of Oxford), with
the aim to discover and validate epigenetic signatures in patients
with ALS to be used as diagnostic and prognostic biomarkers, using
its proprietary EpiSwitch(TM) platform.
Innovate UK has agreed to expand the project to utilise OBD's
Malaysian based ALS network consisting of 30 hospitals, established
by OBD's wholly owned Malaysian subsidiary ("OBDM"), to collect a
South East Asian sample cohort to complement the European cohort
being supplied by the Nuffield departments MND clinic.
The new sample cohort will be used to assess the performance and
adapt the EpiSwitch(TM) assay to a South East Asian cohort with
multiple ethnic backgrounds. This expansion opens up an additional
market for OBD and will provide a greater understanding of the
effects of ethnicity on accurate biomarker stratification of ALS
patients across ethnic groups. The project is due to be completed
by the end of 2017.
OBD's award-winning, proprietary technology platform,
EpiSwitch(TM) aims to accelerate the drug discovery and development
process, improve the success rate of therapeutic product
development and take advantage of the increasing importance of
personalised medicine.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"We are delighted to expand the OBD ALS programme, which started
with NEALS and Massachusetts General Hospital and received the
important support of Innovate UK, into South East Asia. We now have
the opportunity to utilise non-invasive EpiSwitch(TM) biomarkers
well attuned to local Asian ethnic specificities. With our
technology, we are building solutions for quick and effective
diagnosis and prognosis of ALS patients and in the longer term, we
are aiming to provide early symptomatic and pre-symptomatic
diagnosis.
"Regarding prognostic ALS stratification, we are receiving
strong support for our programme from all parties involved and see
its primary application as improving patient care and de-risking
novel ALS therapeutic development."
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar,
CEO
Katie Long, CFO
Stifel Nicolaus Europe
Limited +44 (0)20 7710 7600
Nominated Advisor and
Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital +44 (0)20 7408 4090
Joint Broker
Bidhi Bhoma
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
revenue--generating biotechnology company focused on the discovery
and development of epigenetic biomarkers for use within the
pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFEFWEFWSEIM
(END) Dow Jones Newswires
June 13, 2017 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024